Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,444.25
(
0.58%
)
US TECH 100
28,690.00
(
0.36%
)
Dow Jones
49,693.20
(
-0.14%
)
Brent Oil
104.19
(
0.48%
)
Bitcoin
79,763.84
(
0.60%
)
News Focus
News Focus
Post# of 257556
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (6) Keep Next 10 Report Keyboard Shortcuts
Replies (6) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122977
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 80158

Wednesday, 02/22/2012 8:18:11 PM

Wednesday, February 22, 2012 8:18:11 PM

Post# of 257556
MYL-Biocon FoB portfolio:

• Herceptin: phase-1
• Neulasta: preclinical
• Avastin: process development
• Humira: cell-line development
• Enbrel*: cell-line development
• One undisclosed product at an undisclosed stage

*Presumably not for US market due to AMGN’s recent patent extension.

Source: MYL’s Investor Day webcast (2/21/12).

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (6) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (6) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today